Cambrex to Give Webinar on API Manufacturing Capabilities using Customer Case Studies
Stephanie Harrison, Marketing Manager
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”) is pleased to announce that Bjarne Sandberg, Managing Director of Cambrex Karlskoga and Joe Nettleton, VP of Operations and Site Director of Cambrex Charles City, will present a webinar entitled Quality, Speed, Flexibility and Customer Focus in API Manufacturing: An Introduction of Cambrex through Customer Case Studies on Wednesday, June 11, 2014 at 11 AM EDT (16:00 UK BST/ GMT +1).
The informative webinar will use customer case studies to expand on Cambrex’s commitment working with large, mid-size, emerging and niche pharmaceutical companies in meeting their changing small molecule therapeutic needs and bringing their products to market quickly.
The live broadcast, hosted by Xtalks, includes a slide presentation and a Q&A session. For more information or to register for this webinar, visit: Quality, Speed, Flexibility and Customer Focus in API Manufacturing: An Introduction of Cambrex through Customer Case Studies.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.